The National Institute of Neurological Disorders and Stroke (NINDS) is offering this grant to support the preclinical development of new therapies for resistant epilepsy and epileptogenesis. This program aims to cure epilepsy, prevent its emergence following brain injury, or improve treatment for intractable cases. It facilitates the translation of basic research into therapeutic candidates, focusing on projects with existing therapeutic leads demonstrating activity against the disease target. Supported activities include preclinical optimization and testing, with the expectation that projects will be advanced enough for an IND or IDE application to the FDA by the project’s conclusion. This grant does not support early-stage therapeutic discovery, high-throughput screening, clinical research, basic research, or studies of disease mechanisms. It is a milestone-driven cooperative agreement involving NIH staff participation.
Opportunity ID: 78993
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-11-154 |
| Funding Opportunity Title: | NINDS Cooperative Program in Translational Research for Resistant Epilepsy and Epileptogenesis (U01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 15, 2011 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | May 07, 2013 |
| Current Closing Date for Applications: | May 07, 2013 |
| Archive Date: | Jun 07, 2013 |
| Estimated Total Program Funding: | $3,600,000 |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Special district governments Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Small businesses State governments Private institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign (non-U.S.) components of U.S. Organizations are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The goal of this funding opportunity announcement (FOA), from the National Institute of Neurological Disorders and Stroke (NINDS) is to support preclinical development of new therapies to cure epilepsy, prevent the emergence of epilepsy following brain injury (including status epilepticus, traumatic brain injury, stroke, encephalitis, or other injury) or in other high-risk groups, or to better treat individuals with intractable epilepsy. The program will facilitate solicitation, development, and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing. This program is specifically directed at projects that include therapeutic leads with demonstrated activity against the intended disease target. The program supports preclinical optimization and testing of these leads and projects must be sufficiently advanced that an IND or IDE application to the FDA can be submitted by the end of the project period. The program does not support early-stage therapeutic discovery activities such as high throughput screening. The program also excludes clinical research, basic research, and studies of disease mechanism. This is a milestone-driven cooperative agreement program involving participation of NIH staff in the development of the project plan and monitoring of research progress. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-11-154.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.853 | ADOBE-FORMS-B1 | ADOBE-FORMS-B1 | PKG00040330 | May 05, 2011 | May 07, 2013 | View |
Package 1
Mandatory forms
78993 RR_SF424_1_2-1.2.pdf
78993 RR_OtherProjectInfo_1_3-1.3.pdf
78993 RR_KeyPersonExpanded_1_2-1.2.pdf
78993 PerformanceSite_1_4-1.4.pdf
78993 PHS398_ResearchPlan_1_3-1.3.pdf
78993 PHS398_CoverPageSupplement_1_4-1.4.pdf
78993 PHS398_Checklist_1_3-1.3.pdf
Optional forms
78993 RR_Budget-1.1.pdf
78993 RR_SubawardBudget-1.2.pdf
78993 PHS_CoverLetter_1_2-1.2.pdf
78993 PHS398_ModularBudget-1.1.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
